BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sacco R, Romano A, Mazzoni A, Bertini M, Federici G, Metrangolo S, Parisi G, Nencini C, Giampietro C, Bertoni M, Tumino E, Scatena F, Bresci G. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. J Crohns Colitis. 2013;7:e692-e697. [PMID: 23870727 DOI: 10.1016/j.crohns.2013.06.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
2 Ueno N, Sugiyama Y, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, Kunogi T, Takahashi K, Tanaka K, Ando K, Kashima S, Inaba Y, Moriichi K, Tanabe H, Taruishi M, Saitoh Y, Okumura T, Fujiya M. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study. BMC Gastroenterol 2021;21:316. [PMID: 34362299 DOI: 10.1186/s12876-021-01889-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Outtier A, Ferrante M. Chronic Antibiotic-Refractory Pouchitis: Management Challenges. Clin Exp Gastroenterol 2021;14:277-90. [PMID: 34163205 DOI: 10.2147/CEG.S219556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Woźniak M, Kurnatowska I, Małecka-Panas E, Talar-Wojnarowska R. Leukocytapheresis in patients with inflammatory bowel diseases. Prz Gastroenterol 2021;6:99-105. [PMID: 34276835 DOI: 10.5114/pg.2021.106658] [Reference Citation Analysis]
6 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 45.0] [Reference Citation Analysis]
7 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Domènech E, Grífols JR, Akbar A, Dignass AU. Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective. World J Gastroenterol 2021; 27(10): 908-918 [PMID: 33776362 DOI: 10.3748/wjg.v27.i10.908] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
9 Németh T, Sperandio M, Mócsai A. Neutrophils as emerging therapeutic targets. Nat Rev Drug Discov 2020;19:253-75. [DOI: 10.1038/s41573-019-0054-z] [Cited by in Crossref: 124] [Cited by in F6Publishing: 182] [Article Influence: 62.0] [Reference Citation Analysis]
10 Worel N, Mansouri Taleghani B, Strasser E. Recommendations for Therapeutic Apheresis by the Section "Preparative and Therapeutic Hemapheresis" of the German Society for Transfusion Medicine and Immunohematology. Transfus Med Hemother 2019;46:394-406. [PMID: 31933569 DOI: 10.1159/000503937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 432] [Article Influence: 104.7] [Reference Citation Analysis]
12 Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
13 Domènech E, Panés J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernández F, González-Conde B, García-Sánchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D; ATTICA Study Group by the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa [listed at the end of the article] . Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. J Crohns Colitis 2018;12:687-94. [PMID: 29490024 DOI: 10.1093/ecco-jcc/jjy023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
14 Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC Gastroenterol 2018;18:120. [PMID: 30068300 DOI: 10.1186/s12876-018-0853-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
15 Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S, Osawa S, Sugimoto K, Shimoyama T, Hanai H. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9:170. [PMID: 29977035 DOI: 10.1038/s41424-018-0037-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
16 Ito A, Omori T, Hanafusa N, Tsuchiya K, Nakamura S, Tokushige K. Efficacy and safety of granulocyte adsorption apheresis in elderly patients with ulcerative colitis. J Clin Apher. 2018;33:514-520. [PMID: 29687913 DOI: 10.1002/jca.21631] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
17 Imperiali G, Amato A, Terpin MM, Beverina I, Bortoli A, Devani M, Viganò C; Study Group on IBD (GSMII) . Granulocyte-Monocyte Apheresis in Steroid-Dependent, Azathioprine-Intolerant/Resistant Moderate Ulcerative Colitis: A Prospective Multicenter Study. Gastroenterol Res Pract 2017;2017:9728324. [PMID: 29403531 DOI: 10.1155/2017/9728324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Iizuka M, Etou T, Kumagai M, Matsuoka A, Numata Y, Sagara S. Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis. Intern Med. 2017;56:2705-2710. [PMID: 28924114 DOI: 10.2169/internalmedicine.8428-16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
19 Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol. 2017;11:749-758. [PMID: 28612637 DOI: 10.1080/17474124.2017.1341309] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Nomura O, Osada T, Shibuya T, Ishikawa D, Haga K, Kodani T, Sakamoto N, Ogihara T, Yamaji K, Watanabe S. Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis. J Clin Apher. 2018;33:21-28. [PMID: 28581039 DOI: 10.1002/jca.21555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
21 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 251] [Article Influence: 33.6] [Reference Citation Analysis]
22 Yamamoto T, Tanaka T, Yokoyama T, Shimoyama T, Ikeuchi H, Uchino M, Watanabe T. Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study. Therap Adv Gastroenterol 2017;10:199-206. [PMID: 28203278 DOI: 10.1177/1756283X16679348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
23 Watanabe K, Uchida Y, Sugawara K, Naiki K, Inao M, Nakayama N, Mochida S. Sequential therapy consisting of glucocorticoid infusions followed by granulocyte–monocyte absorptive apheresis in patients with severe alcoholic hepatitis. J Gastroenterol 2017;52:830-7. [DOI: 10.1007/s00535-016-1287-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
24 Maeda T, Sakiyama T, Kanmura S, Hashimoto S, Ibusuki K, Tanoue S, Komaki Y, Arima S, Nasu Y, Sasaki F, Taguchi H, Numata M, Uto H, Tsubouchi H, Ido A. Low concentrations of human neutrophil peptide ameliorate experimental murine colitis. Int J Mol Med. 2016;38:1777-1785. [PMID: 27840892 DOI: 10.3892/ijmm.2016.2795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
25 Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015;25:56-61. [PMID: 26645664 DOI: 10.1016/j.coph.2015.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
26 Yoshimura N, Yokoyama Y, Matsuoka K, Takahashi H, Iwakiri R, Yamamoto T, Nakagawa T, Fukuchi T, Motoya S, Kunisaki R, Kato S, Hirai F, Ishiguro Y, Tanida S, Hiraoka S, Mitsuyama K, Ishihara S, Tanaka S, Otaka M, Osada T, Kagaya T, Suzuki Y, Nakase H, Hanai H, Watanabe K, Kashiwagi N, Hibi T. An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterol. 2015;15:163. [PMID: 26585569 DOI: 10.1186/s12876-015-0390-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
27 Ansary MM, Ishihara S, Oka A, Kusunoki R, Oshima N, Yuki T, Kawashima K, Maegawa H, Kashiwagi N, Kinoshita Y. Apoptotic cells ameliorate chronic intestinal inflammation by enhancing regulatory B-cell function. Inflamm Bowel Dis. 2014;20:2308-2320. [PMID: 25358066 DOI: 10.1097/mib.0000000000000240] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
28 Yokoyama Y, Watanabe K, Ito H, Nishishita M, Sawada K, Okuyama Y, Okazaki K, Fujii H, Nakase H, Masuda T, Fukunaga K, Andoh A, Nakamura S. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. Cytotherapy. 2015;17:680-688. [PMID: 25804800 DOI: 10.1016/j.jcyt.2015.02.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
29 Ikeya K, Sugimoto K, Kawasaki S, Iida T, Maruyama Y, Watanabe F, Hanai H. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig Liver Dis. 2015;47:365-371. [PMID: 25682993 DOI: 10.1016/j.dld.2015.01.149] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
30 Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
31 Yokoyama Y, Matsuoka K, Kobayashi T, Sawada K, Fujiyoshi T, Ando T, Ohnishi Y, Ishida T, Oka M, Yamada M, Nakamura T, Ino T, Numata T, Aoki H, Sakou J, Kusada M, Maekawa T, Hibi T. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice. J Crohns Colitis. 2014;8:981-991. [PMID: 24556083 DOI: 10.1016/j.crohns.2014.01.027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]